BION-1301 + Placebo

Phase 3Active

0 views this week 0 watching⚡ Active

Interest: 44/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

IgA Nephropathy

Conditions

IgA Nephropathy, Immunoglobulin A Nephropathy

Trial Timeline

Jul 6, 2023 → Jun 7, 2028

NCT ID

NCT05852938

About BION-1301 + Placebo

BION-1301 + Placebo is a phase 3 stage product being developed by Novartis for IgA Nephropathy. The current trial status is active. This product is registered under clinical trial identifier NCT05852938. Target conditions include IgA Nephropathy, Immunoglobulin A Nephropathy.

What happened to similar drugs?

6 of 20 similar drugs in IgA Nephropathy were approved

Approved (6) Terminated (3) Active (11)

✅Anplag(Sarpogrelate) + PlaceboYuhanApproved

🔄olmesartan medoxomil + Placebo TabletsDaiichi SankyoPhase 3

❌Rituximab + cyclosporineSun PharmaceuticalPhase 3

❌Atrasentan + PlaceboAbbViePhase 3

✅Candesartan Cilexetil + Candesartan Cilexetil + Candesartan Cilexetil 32mgAstraZenecaApproved

✅CyclosporineNovartisApproved

🔄LNP023NovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05852938	Phase 3	Active	Jul 6, 2023	Jun 7, 2028	IgA Nephropathy

Competing Products

20 competing products in IgA Nephropathy

See all competitors

Product	Company	Stage	Hype Score
Anplag(Sarpogrelate) + Placebo	Yuhan	Approved	43
CS-3150 + placebo	Daiichi Sankyo	Phase 2	35
olmesartan medoxomil + Placebo Tablets	Daiichi Sankyo	Phase 3	40
Beraprost sodium	Astellas Pharma	Pre-clinical	22
Tacrolimus + Placebo	Astellas Pharma	Phase 2	35
Rituximab + cyclosporine	Sun Pharmaceutical	Phase 3	32
Placebo + LY3016859	Eli Lilly	Phase 1/2	32
Dipeptidyl-Peptidase IV Inhibitors + Glucagon-Like Peptide 1	Eli Lilly	Pre-clinical	26
HR19042 Capsules + Placebo	Jiangsu Hengrui Medicine	Phase 2	35
HR19042 Capsule, Tarpeyo®, Budenofalk®	Jiangsu Hengrui Medicine	Phase 1	29
HR19042 capsule	Jiangsu Hengrui Medicine	Phase 1	29
Atrasentan + Placebo	AbbVie	Phase 3	32
Atrasentan	AbbVie	Phase 2	35
Candesartan Cilexetil + Candesartan Cilexetil + Candesartan Cilexetil 32mg	AstraZeneca	Approved	43
ALXN1920 + Placebo	AstraZeneca	Phase 2	42
Candesartan	AstraZeneca	Pre-clinical	26
Placebo + Atacicept 25 mg + Atacicept 75 mg	Merck	Phase 2	27
MAU868 + Placebo	Novartis	Phase 2	27
Atrasentan	Novartis	Phase 2	39
Cyclosporine	Novartis	Approved	39